Our Funds
Established a portfolio of early stage medical device companies that looked to solve real problems.
Created investment opportunities that allowed direct engagement into company operations.
Continued investing in technologies that improve outcomes & reduce healthcare system costs.
The Opportunity Fund leverages the foundation that our Seed and Accelerator Funds have built since 2017.
Representative Investments
Embody, Inc., is a regenerative medicine company focused on the development and commercialization of implantable medical devices to address the unmet demands in soft tissue restoration and regeneration.
Shoulder Innovations’ InSet™ Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. IPO on July 31, 2025. Now trading on NYSE under ‘SI’.
SPDx’s solution expands the revenue capacity of any surgical facility. SPDx provides sterile processing and logistic support that unlocks the potential to perform multiple total joints in an ASC.
News and Updates
SpinTech MRI Appoints Brian Martin as Chief Executive Officer to Lead Next Phase of Commercial Growth
Experienced medical technology executive to accelerate commercialization, strategic partnerships, and market expansion following successful financing
Shoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlook
Generates First Quarter Net Revenue Growth of 65% Year-Over-Year Shoulder Innovations, Inc. (NYSE: SI), a
cultivate(MD) Focus Fund Announces Initial Capital Deployments
The Focus Fund is cultivate(MD)’s fifth vehicle: a 2031-horizon strategy to identify, support, and exit
Capitan Orthopedics, Inc. Announces Breakthrough Device Designation for its SupraSpacer™ Implant
cultivate(MD) portfolio company Capitan Orthopedics, Inc. announced that it has been granted Breakthrough Device Designation